Gilead Sciences Ltd Sales & Marketing Jobs

This profile is a brief introduction for people seeking employment in pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, or pharmaceutical clinical research associates who may be considering working for Gilead Sciences Ltd.

Gilead Corporate Overview

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Gilead Worldwide

Gilead, with more than 2700 employees worldwide, has operations in North America, Europe and Australia.

In North America, corporate headquarters are based in Foster City, California, with additional operations in San Dimas, California; Durham, North Carolina; Seattle, Washington; Westminster, Colorado; and Alberta & Toronto, Canada.

International operations are based in Uxbridge, United Kingdom and Dublin, Ireland. Additionally, sales and marketing organizations are located in the following cities: Athens, Greece; Cambridge, United Kingdom; Lisbon, Portugal; Madrid, Spain; Melbourne, Australia; Milan, Italy; Munich, Germany, Paris, France, Istanbul, Turkey and Vienna, Austria.

Marketed Products

Gilead takes great pride in its unique portfolio of therapeutics, designed to advance the care of patients suffering from life-threatening infectious diseases. Currently, our portfolio includes ten marketed products: Atripla^®(efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for HIV-1 infection in adults intended as a stand-alone therapy or in combination with other antiretrovirals. The product combines Sustiva^® (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada^® (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences. Atripla was cleared for marketing in the United States in July 2006. Truvada^® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose combination of Emtriva^® (emtricitabine) and Viread^® (tenofovir disoproxil fumarate) for the treatment of HIV infection, in combination with other antiretroviral agents. Truvada received approval from the United States Food and Drug Administration (FDA) in August 2004 and was approved by the European Commission in February 2005. Viread^® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor for the treatment of HIV infection, in combination with other antiretroviral agents. Viread was cleared for marketing in the United States in October 2001 and in Europe in February 2002. Emtriva^® (emtricitabine) is a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection, in combination with other antiretroviral agents. Emtriva was cleared for marketing in the United States in July 2003 and in Europe in October 2003. Emtriva oral solution received marketing approval from the European Commission in October 2003 and the FDA in September 2005. AmBisome^® (amphotericin B) liposome for injection is a treatment for life-threatening, systemic fungal infections. AmBisome was cleared for marketing in the United States in 1997, and first cleared for marketing in Europe in 1990. Hepsera^® (adefovir dipivoxil) is a once-daily, orally-administered nucleotide analogue reverse transcriptase inhibitor for the treatment of patients with chronic hepatitis B. Hepsera was approved in the United States in September 2002 and in Europe in March 2003. Tamiflu^®(oseltamivir phosphate) is the first neuraminidase inhibitor in pill form for the treatment and prevention of influenza A and B. Tamiflu was cleared by the U.S. FDA for the treatment of influenza in October 1999, for the prevention of influenza in November 2000, and for the treatment of children one year and older in December 2000. Tamiflu was approved in Europe in June 2002. Flolan^® (epoprostenol sodium) for injection was approved by the FDA in 1995 and is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond adequately to conventional therapy. Vistide^®(cidofovir injection) is an antiviral for the treatment of cytomegalovirus retinitis in patients with AIDS. Vistide was cleared for marketing in the United States in June 1996 and in Europe in May 1997. Macugen^® (pegaptanib sodium injection) is a treatment for neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision. Macugen was approved by the U.S. FDA in December 2004.

Discovery and Development

At Gilead, we employ the most advanced scientific tools to develop therapeutics for the treatment of life-threatening diseases. Our goal is to create innovative therapeutics with enhanced delivery modes, favorable resistance profiles, fewer side effects and stronger efficacy.

Advanced Care

Gilead strives to advance the care of patients by developing medicines that make a significant difference in the treatment of life-threatening diseases. Our mission guides our relationships with physicians, patients and their caregivers, and our employees.

Physicians - We provide physicians with resources to better care for their patients by rapidly and efficiently developing innovative therapeutics.

Patients and Caregivers - We collaborate with patient advocates, design drugs to enhance treatment regimens, and implement effective patient assistance programs to ensure our efforts help meet the needs of patients and their caregivers.

Employees - We promote teamwork, accountability, integrity and excellence. Gilead provides opportunities for career growth, celebrates success and values employee commitment to making a difference in the lives of the patients we serve.